Compounded BPC-157

No. The large majority of BPC-157 research is preclinical — conducted in rats or in cell cultures — and well-controlled human clinical trials are lacking. The animal data on tendon, soft-tissue, and gut healing are consistent and biologically plausible, but they have not been confirmed in people. BPC-157 should be understood as investigational: it may support recovery, but its benefits in humans are unproven and it is not FDA-approved.

Because human data are limited, there is no established timeline. Protocols are typically run as courses of about 4–8 weeks, and patients who choose it for a nagging soft-tissue complaint generally reassess with their doctor at the end of a course. Anything you notice is anecdotal rather than the result of controlled trials, and individual responses vary widely.

BPC-157 is most often given as a daily subcutaneous injection using a small insulin syringe. Some protocols place the injection subcutaneously near the affected area on the theory of local action, though this targeting is based on preclinical reasoning rather than proven human data. Your prescribing doctor will give you specific instructions for your protocol.

BPC-157 has shown a favorable safety profile in animal studies, with no lethal dose reached in rodents. The most discussed theoretical concern is that, because it promotes angiogenesis (new blood-vessel growth) in animals, it could in principle support unwanted tissue or tumor growth. For that reason it is generally avoided in anyone with a personal or family history of cancer, and any new lump or unusual symptom should be reported immediately. Long-term human safety has not been established.

Some patients combine BPC-157 with peptides like TB-500 for recovery goals, but this should always be doctor-supervised, and combining two investigational compounds compounds the uncertainty in the evidence. Your protocol is individualized, and your prescribing doctor decides whether any combination is appropriate for you.

BPC-157 is included on the World Anti-Doping Agency (WADA) Prohibited List under the category of agents affecting tissue repair. Competitive athletes subject to anti-doping testing should not use it. If you compete under any sporting body, confirm the current rules before considering this or any peptide.

Yes. A US-licensed doctor reviews your history, goals, and any relevant imaging or labs before deciding whether a prescription is appropriate. Because BPC-157 is investigational, the doctor will also discuss the limits of the evidence and the theoretical risks with you so you can make an informed decision.

Peptide12 partners with state-licensed compounding pharmacies that hold state and federal licensure and undergo regular USP <797> sterility audits. Every batch is third-party tested for identity, potency, sterility, and endotoxin before release. Compounded BPC-157 is not FDA-approved as a finished drug product but is prepared from FDA-regulated active ingredients under individualized prescription.

No. Compounded, investigational peptides like BPC-157 are not covered by commercial insurance. Some patients use HSA or FSA funds where eligible. Your care team can help you understand the costs before you start.